section name header

Pronunciation

DAP-sohn

Classifications

Therapeutic Classification: leprostatic agent, anti-infectives

Indications

REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Spectrum:

Pharmacokinetics

Absorption: Slowly absorbed (70–80%) following oral administration; acidic environment promotes absorption.

Distribution: Widely distributed; crosses the placenta and enters breast milk in significant concentrations.

Protein Binding: Dapsone: 70–90%; MADDS: 99%.

Metabolism/Excretion: Mostly metabolized by the liver to monoacetyl dapsone (MADDS), its major metabolite, which is then metabolized back to dapsone.

Half-life: 10–50 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POunknownunknownunknown
Topicalunknownunknownunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: STEVENS-JOHNSON SYNDROME, exfoliative dermatitis, hypersensitivity reactions (including erythema nodosum leprosum), photosensitivity, systemic lupus erythematosus.

EENT: blurred vision, pharyngitis (topical), tinnitus.

GI: vomiting, abdominal pain, HEPATOTOXICITY, nausea, PANCREATITIS.

Hemat: hemolytic anemia, AGRANULOCYTOSIS, METHEMOGLOBINEMIA, reticulocytosis.

Neuro: headache, insomnia, mood changes, peripheral neuropathy, tonic-clonic movements (topical), vertigo.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

see Calculator

Leprosy

Dermatitis Herpetiformis

Acne Vulgaris

Pneumocystis jiroveciiPneumonia

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Aczone